Sofinnova Partners
Also known as Sofinnova, Sofinnova Partners SAS
Paris life-sciences VC founded in 1972; seven strategies from company creation to crossover in biopharma, medtech, digital medicine and industrial biotech; over €4bn AUM (2026).
Paris-based life-sciences VC; distinct from the US firm Sofinnova Investments (Menlo Park).
- HEADQUARTERS
- Paris, France
- FOUNDED
- 1972
- AUM
- €4B (2026)
- OUTSIDE CAPITAL
- Yes
- TEAM LISTED
- 12 people
Focus
- STAGES
- SeedSeries ASeries BGrowth
- ASSET MIX
- Venture capital
- GEOGRAPHY
- EuropeUnited States
Investment arms & vehicles
- Flagship early-stage biopharma and medtech fund; founding or lead investor (Capital XI, €650M, 2025)
- In-house medtech accelerator creating early-stage medtech companies (MD Start IV, €82M, 2026)
- Growth-stage biotech and medtech companies preparing for commercialisation
- Early-stage sustainable companies in agriculture, chemicals, food and materials
- Early-stage investments in Italian science
- Early-stage techbio and healthtech at the intersection of biology, data and computation
- Biotech accelerator building European biotech start-ups with research organisations
Overview
Sofinnova Partners is a life-sciences venture capital firm founded in 1972 and based in Paris, London and Milan, managed by an AMF-approved portfolio management company. It invests from seed to later stage across seven strategies: Capital (flagship early-stage biopharma and medtech), MD Start (medtech company creation), Crossover, Industrial Biotech, Telethon, Digital Medicine and Biovelocita. It states it has backed more than 500 companies and manages over €4 billion. In November 2025 it closed Sofinnova Capital XI at €650M, and in September 2026 Sofinnova MD Start IV at €82M.
PORTFOLIO (12)
- AbivaxNOTABLEBiotech & Life Sciences
- Ascendis PharmaNOTABLEBiotech & Life Sciences
- HighLifeHealthTech · since 2026
- BionyraBiotech & Life Sciences
- AAVantgarde BioBiotech & Life Sciences
- DNA ScriptBiotech & Life Sciences
- BioptimusArtificial Intelligence
- Latent LabsArtificial Intelligence
- CorWaveHealthTech
- Moon SurgicalHealthTech
- LimFlowHealthTech · Acquired
- MyricxBiotech & Life Sciences · Acquired
People
- Antoine PapiernikChairman & Managing Partner · source
- Graziano SeghezziManaging Partner; legal representative · source
- Henrijette RichterManaging Partner · source
- Maina BhamanPartner, Capital Strategy · source
- Anta GkelouPartner, Capital Strategy · source
- Karl NaeglerPartner, Capital Strategy · source
- Cedric MoreauPartner, Crossover Strategy · source
- Michael KrelPartner, Industrial Biotech Strategy · source
- Anne OsdoitPartner, MD Start Strategy · source
- Lucia FaccioPartner, Telethon Strategy · source
- Edward KliphuisPartner, Digital Medicine Strategy · source
- Christophe BlancheChief Financial Officer · source
Links
Frequently asked questions
Sofinnova Partners is a VC fund based in Paris, France, founded in 1972.
Yes. Sofinnova Partners invests its own capital in private companies.
Sofinnova Partners invests at Seed, Series A, Series B and Growth stages in Biotech & Life Sciences, HealthTech, Artificial Intelligence and Food & Agriculture.
Key people at Sofinnova Partners include Antoine Papiernik (Chairman & Managing Partner), Graziano Seghezzi (Managing Partner; legal representative), Henrijette Richter (Managing Partner) and Maina Bhaman (Partner, Capital Strategy).
Sofinnova Partners's investments include Abivax, Ascendis Pharma, HighLife, Bionyra, AAVantgarde Bio, DNA Script, Bioptimus and Latent Labs, among others.
The most recent publicly reported investment by Sofinnova Partners is HighLife ($90M+ (€80M) financing, co-lead), announced in Sep 2026.
Sofinnova Partners states that it accepts submissions through its official contact page.
Yes. Sofinnova Partners manages capital from outside investors.